ADMA BIOLOGICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ADMA BIOLOGICS, INC. (ADMA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $774.78 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2020-11-05
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-09-30 was $774.78K, a 19.07% increase year-over-year.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-06-30 was $715.61K, a 1.53% decline year-over-year.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-03-31 was $676.55K, a 6.16% increase year-over-year.
- ADMA BIOLOGICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2019-09-30 was $650.67K, a 12.65% increase year-over-year.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month |
|---|---|---|---|
| 2020-09-30 | $774.78K 10-Q · filed 2020-11-05 | $1.49M derived: sum of 2 quarters · filed 2020-11-05 | $2.17M derived: sum of 3 quarters · filed 2020-11-05 |
| 2020-06-30 | $715.61K 10-Q · filed 2020-11-05 | $1.39M derived: sum of 2 quarters · filed 2020-11-05 | |
| 2020-03-31 | $676.55K 10-Q · filed 2020-11-05 | ||
| 2019-09-30 | $650.67K 10-Q · filed 2020-11-05 | $1.38M derived: sum of 2 quarters · filed 2020-11-05 | $2.01M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $726.74K 10-Q · filed 2020-11-05 | $1.36M derived: sum of 2 quarters · filed 2020-11-05 | |
| 2019-03-31 | $637.26K 10-Q · filed 2020-11-05 | ||
| 2018-09-30 | $577.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.11M derived: sum of 2 quarters · filed 2019-11-06 | $1.63M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $535.39K 10-Q · filed 2019-08-08 | $1.05M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $514.78K 10-Q · filed 2019-08-08 | ||
| 2017-09-30 | $505.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $817.09K derived: sum of 2 quarters · filed 2017-11-03 | $1.05M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $311.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $547.24K 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $235.88K 10-Q · filed 2017-05-12 | ||
| 2016-09-30 | $262.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $573.91K derived: sum of 2 quarters · filed 2016-11-10 | $996.09K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $310.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-12 | $733.13K 10-Q · filed 2016-08-12 | |
| 2016-03-31 | $422.18K 10-Q · filed 2016-05-13 | ||
| 2015-09-30 | $447.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $834.59K derived: sum of 2 quarters · filed 2015-11-10 | $1.22M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $386.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $773.73K 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $387.07K 10-Q · filed 2015-05-12 | ||
| 2012-06-30 | $154.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $200.35K 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $46.25K 10-Q · filed 2012-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |